| Application | Recommended Dilution |
|---|---|
| IHC | 1:50-1:200 |
CUSABIO employs a rigorous approach to produce the CCL19 antibody. Initially, an animal is immunized with a synthetic peptide derived from human CCL19, triggering an immune response for antibody generation. The resulting CCL19 antibody is then sequenced, and the antibody gene is synthesized accordingly. The gene is inserted into plasma vectors, which are subsequently transfected into mammalian cells using a lipid-based transfection reagent. Following transient expression, CUSABIO purifies the recombinant antibodies against CCL19 from the culture medium. This high-quality CCL19 recombinant monoclonal antibody is specifically designed for ELISA and IHC applications to detect human CCL19 protein accurately and reliably.
Email: support@cusabio.com
Distributors Worldwide